Both insurers and healthcare organizations are against the Medical For All Act introduced by House Democrats this week.

A line of defense is emerging for top prescription drug companies whose topexecutives will be pulled before Congress on Tuesday to testify about high prices for medicine: They are not to blame.

Laura Lucero Y Ruiz De Gutierrez has a heart condition and fibromyalgia and is in danger of developing diabetes. She has health insurance through her husband’s job. But, between the $800 monthly premium for the couple’s coverage and the $2,100 deductible she has to pay down before insurance starts picking up the tab, she doesn’t feel she can afford to go to the doctor when she needs to.

There is increasingly a push for benefit advisers to bring new technology to clients, but they may need to be more strategic when using it.

California would become the first state to block pharmaceutical companies from paying generic competitors to delay the release of lower-priced drugs under a bill announced Wednesday.

Even before Democrats finish drafting bills to create a single-payer health care system, the health care and insurance industries have assembled a small army of lobbyists to kill “Medicare for all,” an idea that is mocked publicly but is being greeted privately with increasing seriousness.